From Europe. For the global patent community.
  • JUVE Patent PaceMaker
  • Advertiser Login
  • Firm Rankings
  • Cases
  • Legal Commentary
  • People & Business
  • Sponsored: Firm Profiles
    • Taylor Wessing
    • Simmons + Simmons LLP
    • PENTARC Rechtsanwälte PartG mbB
    View all Firm Profiles
    Sponsored: Expert Profiles
    • Dr. Andreas Ledl Maiwald Intellectual Prop…
    • Jürgen Feldmeier, LL.M. Prüfer and Partner mbB
    • Dr. Nora E. Wessendorf, LL.M. Taylor Wessing
    View all Expert Profiles
    Sponsored Content
    • IP Monetization Outlook: Key Insights… by Burford Capital
    • A whole-of-market-evidence approach t… by BRELA / FRANDLY
    • FRAND Rate-Setting: Convergence on Pr… by BRELA / FRANDLY
    View all Sponsored Content
Trending Topics:
  • Dutch patent market
  • Interviews
  • UK patent courts
  • Unified Patent Court
JUVE Patent Year in review 2024

Year in review 2024

People & Business
Year in review 2024

Top 10 most-read articles of the year 2024

For the second year running, pharmaceuticals and medical devices cases dominate JUVE Patent's ten most-read articles. Top of the list is the report on ...

30 December 2024 by Laura King
Cases
top 10 patent cases, CJEU, UPC
Year in review 2024

Top 10 patent cases of the year 2024

The year 2024 was dominated by the UPC. Under the watchful eyes of the patent world, the new court is making patent history with its numerous rulings ...

27 December 2024 by Konstanze Richter
People & Business
Year in review 2024

JUVE Patent's Ones to Watch 2024 - the full overview

JUVE Patent identified 17 rising stars as Ones to Watch in 2024. For the first time since JUVE Patent began awarding this accolade, almost half of the ...

24 December 2024 by Mathieu Klos
Popular
  • Novo Nordisk loses another patent behind Ozempic and Wegovy drugs
  • Cases at Paris patent chamber decline for first time in years
  • UPC Court of Appeal hears Sanofi’s challenge over cabazitaxel patent revocation
© 2026 Juve Patent
 Created with Sketch. LinkedIn
  • Team
  • About us
  • Media Information
  • General Terms and Conditions
  • PaceMaker General Terms & Conditions
  • Privacy Policy
  • Legal Notice
  • Whistleblowing policy
  • Dealing with Artificial Intelligence (AI)
Back to top
Advertising